✦ LIBER ✦

NGX 267 meets primary endpoint in phase II xerostomia trial

Book ID: 120841692
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2008
Weight: 133 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200816670-00041

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Saxagliptin meets primary safety endpoin

Saxagliptin meets primary safety endpoint in large, phase IV trial

✍ Wagner, Mathilde; Maggiori, Léon; Ronot, Maxime; Paradis, Valérie; Vilgrain, Val 📂 Article 📅 2013 🏛 Adis International Limited (now part of Wolters Kl ⚖ 124 KB

Paclitaxel added to the cisplatin/etopos

Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer — the use of complete response rate as the primary endpoint in phase II trials

✍ Dowlati, Afshin; Crosby, Lori; Remick, Scot C.; Makkar, Vinit; Levitan, Nathan 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 80 KB